<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Subdural hematoma in adults: Management and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Subdural hematoma in adults: Management and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Subdural hematoma in adults: Management and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William McBride, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            José Biller, MD, FACP, FAAN, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alejandro A Rabinstein, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subdural hematoma (SDH) is a form of intracranial hemorrhage characterized by bleeding into the space between the dural and arachnoid membranes surrounding the brain.
        </p>
        <p>
         The management and prognosis of SDH will be discussed here. A rapid overview summarizes the clinical features, evaluation, and management of SDH in adults  (
         <a class="graphic graphic_table graphicRef132691" href="/z/d/graphic/132691.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Other aspects of SDH are reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1105.html" rel="external">
          "Subdural hematoma in adults: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6520.html" rel="external">
          "Intracranial subdural hematoma in children: Epidemiology, anatomy, and pathophysiology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6534.html" rel="external">
          "Intracranial subdural hematoma in children: Clinical features, evaluation, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Other forms of intracranial hemorrhage are discussed elsewhere.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1107.html" rel="external">
          "Intracranial epidural hematoma in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/90075.html" rel="external">
          "Aneurysmal subarachnoid hemorrhage: Epidemiology, risk factors, and pathogenesis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1111.html" rel="external">
          "Nonaneurysmal subarachnoid hemorrhage"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1114.html" rel="external">
          "Perimesencephalic nonaneurysmal subarachnoid hemorrhage"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1133.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4825.html" rel="external">
          "Traumatic brain injury: Epidemiology, classification, and pathophysiology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H941411125">
         <span class="h1">
          INITIAL MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         SDH can be a neurologic emergency that may cause irreversible brain injury and death caused by hematoma expansion, elevated intracranial pressure (ICP), or brain herniation. Patients with acute or chronic SDH require urgent initial assessment of clinical status to determine the need for surgery and the medical interventions needed to mitigate adverse outcomes  (
         <a class="graphic graphic_algorithm graphicRef134178" href="/z/d/graphic/134178.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H282543372">
         <span class="h2">
          Initial assessment and emergency management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial assessment of SDH includes airway management for patients with drowsiness or severe bulbar symptoms. Patients with SDH associated with trauma should also undergo a structured primary survey to identify and prioritize management of other injuries. The initial evaluation of adult patients with trauma is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/13854.html" rel="external">
          "Initial management of trauma in adults", section on 'Primary evaluation and management'
         </a>
         .)
        </p>
        <p>
         A neurologic examination is performed to determine the severity of initial neurologic deficits and provide a baseline to assess subsequent deterioration. The clinical assessment typically includes the Glasgow Coma Scale  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 2
         </a>
         ), a simple clinical scale to quantify deficits for patients with brain injury.
        </p>
        <p class="headingAnchor" id="H2608224434">
         <span class="h2">
          Management of antithrombotic medications
         </span>
        </p>
        <p class="headingAnchor" id="H150347935">
         <span class="h3">
          Reversing anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with SDH who are taking anticoagulants, we discontinue these medications and give agents to reverse anticoagulant effects. We balance the hemorrhagic risks of anticoagulation with the thrombotic risks of reversal at an individual level. Reversal of anticoagulation is required for patients with acute or chronic SDH prior to surgical intervention. In addition, for most patients with acute SDH who are managed nonoperatively, we reverse anticoagulation to reduce the risk of SDH enlargement.
        </p>
        <p>
         By contrast, for some patients with a chronic or small acute SDH and no signs of increased ICP who are receiving anticoagulation for a compelling indication such as a mechanical heart valve, the risk-benefit calculation may favor continued anticoagulation with close observation of neurologic status. For such patients, we anticoagulate with heparin during the acute setting whenever possible because it is typically quicker to reverse in the event of hematoma expansion. (See
         <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">
          "Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures", section on 'Management of bleeding'
         </a>
         .)
        </p>
        <p>
         If reversal of anticoagulation is indicated, the appropriate intervention depends upon the anticoagulant the patient is taking, the time since last dosage, and the urgency with which reversal is needed. Some patients prescribed anticoagulant medications may not require reversal agents if laboratory testing or the time interval since last dose indicates they are effectively not anticoagulated. For other patients with a medication-related coagulopathy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Warfarin
         </strong>
         – Four-factor prothrombin complex concentrate (4F PCC) along with intravenous
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         is preferred for patients with serious or life-threatening bleeding; the dose of 4F PCC may need to be repeated while awaiting the effects of drug discontinuation  (
         <a class="graphic graphic_table graphicRef89478" href="/z/d/graphic/89478.html" rel="external">
          table 3
         </a>
         ). If a 4F PCC is not available, a three-factor product may be used with recombinant activated factor VII or fresh frozen plasma (FFP). Reversal of anticoagulation in this setting is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">
          "Reversal of anticoagulation in intracranial hemorrhage", section on 'Warfarin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dabigatran
         </strong>
         – We use the reversal agent
         <a class="drug drug_general" data-topicid="104819" href="/z/d/drug information/104819.html" rel="external">
          idarucizumab
         </a>
         for patients with potentially life-threatening bleeding including SDH. If idarucizumab is not available, an activated PCC such as factor eight inhibitor bypassing agent (FEIBA) can be used  (
         <a class="graphic graphic_table graphicRef112299" href="/z/d/graphic/112299.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">
          "Reversal of anticoagulation in intracranial hemorrhage", section on 'Dabigatran'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Direct factor Xa inhibitors (eg,
         </strong>
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         <strong>
          ,
         </strong>
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         <strong>
          ,
         </strong>
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         <strong>
          )
         </strong>
         – We use either
         <a class="drug drug_general" data-topicid="117811" href="/z/d/drug information/117811.html" rel="external">
          andexanet alfa
         </a>
         or a 4F PCC to reverse the effects of direct factor Xa inhibitors  (
         <a class="graphic graphic_table graphicRef112299" href="/z/d/graphic/112299.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">
          "Reversal of anticoagulation in intracranial hemorrhage", section on 'Apixaban, edoxaban, and rivaroxaban'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">
          Unfractionated heparin
         </a>
         <strong>
          and low molecular weight heparins
         </strong>
         –
         <a class="drug drug_general" data-topicid="9831" href="/z/d/drug information/9831.html" rel="external">
          Protamine sulfate
         </a>
         is used to reverse the effect of heparin agents. The dose depends upon the type of heparin used (unfractionated versus low molecular weight agents), the dose of heparin given, and the time elapsed since that dose.
         <a class="drug drug_general" data-topicid="117811" href="/z/d/drug information/117811.html" rel="external">
          Andexanet alfa
         </a>
         may be used for patients taking low molecular weight heparin. (See
         <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">
          "Reversal of anticoagulation in intracranial hemorrhage", section on 'Unfractionated heparin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">
          "Reversal of anticoagulation in intracranial hemorrhage", section on 'LMW heparin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4087092684">
         <span class="h3">
          Patients on antiplatelets
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiplatelet medications are typically stopped at the time of diagnosis for most patients with either acute SDH or large or symptomatic chronic SDH to reduce the risk of hematoma enlargement. However, we balance the thrombotic risks of discontinuation with the hemorrhagic risks of continuing antiplatelets at an individual level. We may continue antiplatelet medications during acute monitoring for selected patients at low risk of hematoma expansion and high risk of thrombosis such as those with established atherosclerotic disease or who have undergone intravascular stent placement and who have small or chronic SDH. (See
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">
          "Antithrombotic therapy for elective percutaneous coronary intervention: General use"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">
          "Overview of carotid artery stenting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15217.html" rel="external">
          "Endovascular techniques for lower extremity revascularization", section on 'Antiplatelet therapy'
         </a>
         .)
        </p>
        <p>
         We do
         <strong>
          not
         </strong>
         give platelet transfusion to most patients taking antiplatelet medications who present with SDH. The available data from trials of patients with spontaneous intracerebral hemorrhage suggest that platelet transfusions may be hazardous and should be avoided. (See
         <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">
          "Spontaneous intracerebral hemorrhage: Acute treatment and prognosis", section on 'Reverse anticoagulation'
         </a>
         .)
        </p>
        <p>
         We reserve platelet transfusions for those with specific indications, including those with a thrombocytopenia (&lt;100,000/microL) or a known platelet defect. (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Platelet function disorders'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4276259408">
         <span class="h2">
          Identifying patients with an indication for surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with SDH require urgent surgical treatment at the time of initial presentation based on severity of imaging findings or clinical exam. Surgery may help to prevent irreversible brain injury and death caused by hematoma expansion, elevated ICP, and brain herniation. The benefits of surgery for patients with SDH are based on the severity of the lesion, the likelihood of subsequent deterioration, and the potential for recovery with surgery [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The indications for and timing of surgery and operative approaches for patients with SDH are discussed below. (See
         <a class="local">
          'Surgical indications and approaches'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3442938969">
         <span class="h1">
          SURGICAL INDICATIONS AND APPROACHES
         </span>
        </p>
        <p class="headingAnchor" id="H612020479">
         <span class="h2">
          Neurosurgical consultation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurosurgical consultation may be obtained for most patients with acute or symptomatic chronic SDH. Immediate neurosurgical consultation for urgent surgical evacuation is required for patients with SDH and any of the following clinical and imaging features:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical features
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dilated pupil(s)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rapid or progressive deterioration (including new drowsiness) on examination
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Drop of ≥2 points on Glasgow Coma Scale (GCS) score  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cushing triad (bradycardia, respiratory depression, hypertension)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imaging features
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maximal clot thickness &gt;10 mm
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Shift of midline structures &gt;5 mm, measured at the septum pellucidum  (
         <a class="graphic graphic_diagnosticimage graphicRef68102" href="/z/d/graphic/68102.html" rel="external">
          image 1
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hydrocephalus or brainstem compression  (
         <a class="graphic graphic_diagnosticimage graphicRef132682" href="/z/d/graphic/132682.html" rel="external">
          image 2
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         SDH associated with structural brain lesion (eg, skull fracture, arteriovenous malformation)
        </p>
        <p>
        </p>
        <p>
         For other patients with acute SDH, we monitor nonoperatively with close neurologic examinations and surveillance imaging for clinical or radiographic deterioration. (See
         <a class="local">
          'Nonoperative management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1485961882">
         <span class="h2">
          Acute subdural hematoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urgent surgical hematoma evacuation is required for patients with acute SDH and clinical signs attributable to brain herniation or elevated intracranial pressure (ICP) and for such patients who have evidence of neurologic deterioration since the time of injury. We suggest urgent surgical hematoma evacuation for patients with SDH thickness &gt;10 mm or midline shift &gt;5 mm on initial brain scan  (
         <a class="graphic graphic_algorithm graphicRef134178" href="/z/d/graphic/134178.html" rel="external">
          algorithm 1
         </a>
         ). The benefits of surgery for those with an indication based on SDH size alone may be less certain for patients with significant cerebral atrophy and/or with minimal midline shift, patients older than 75 years of age, and those with medical comorbidities that are at elevated surgical risk [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         For other patients with acute SDH, we monitor nonoperatively with close neurologic examinations and surveillance imaging for clinical or radiographic deterioration. (See
         <a class="local">
          'Nonoperative management'
         </a>
         below.)
        </p>
        <p>
         Guidelines from an expert panel published in 2006 recommended surgical evacuation to reduce the risk of mortality or further morbidity for patients with severe or progressive symptoms and those with large acute SDH [
         <a href="#rid1">
          1
         </a>
         ]. Clinical thresholds for surgery included a drop in the GCS score by ≥2 points from the time of injury to hospital admission and the presence of asymmetric or fixed and dilated pupils [
         <a href="#rid1">
          1
         </a>
         ]. Imaging thresholds for surgery included an SDH clot thickness &gt;10 mm or &gt;5 mm midline shift, regardless of clinical findings. Larger SDH volumes are associated with worse outcomes. In a retrospective study of 174 patients undergoing surgery for SDH, the mortality rate increased with size of clot thickness from 10 percent for patients when SDH &lt;10 mm to 90 percent when SDH &gt;30 mm [
         <a href="#rid3">
          3
         </a>
         ]. In another study of initial nonoperative management of 31 patients with acute SDH, hematoma thickness &gt;10 mm and midline shift &gt;5 mm on initial imaging were associated with subsequent neurologic deterioration and need for surgery [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Common surgical options for acute SDH include craniotomy, craniostomy (eg, burr hole trephination), and decompressive craniectomy [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Craniotomy
         </strong>
         – Craniotomy is often the preferred surgical technique for patients with acute SDH without underlying brain swelling who undergo hematoma evacuation. The procedure involves removal of a small section of skull to expose and drain the SDH. The skull flap is replaced and secured at the end of the procedure. Craniotomy provides better access and more effective drainage of acute SDH than the more limited burr hole craniostomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Craniectomy
         </strong>
         – Decompressive craniectomy involves removal of a section of the skull to permit wide exposure of the underlying dura mater overlying the SDH. This technique facilitates SDH evacuation and can help reduce morbidity from associated or anticipated brain swelling [
         <a href="#rid5">
          5
         </a>
         ]. The removed skull flap is replaced in a delayed fashion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Craniostomy
         </strong>
         – Craniostomy involves drilling a small hole through the skull to gain rapid access to SDH and/or to minimize incision size. It may be performed using burr hole trephination or twist drill techniques [
         <a href="#rid6">
          6
         </a>
         ]. Craniostomy is less invasive than craniotomy techniques and can be performed at the bedside for emergency situations. It may also be used to reduce SDH volume in patients with mixed-density (acute-on-chronic) SDH [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Surgical technique for SDH evacuation varies by severity of injury, surgeon experience/preference, and available resources. Craniotomy may be preferred to minimize operative time and wound complications while craniectomy may be preferred to reduce risk of morbidity or reoperation from subsequent brain swelling [
         <a href="#rid5">
          5
         </a>
         ]. In a multicenter trial of 462 patients with symptomatic acute SDH who were randomized to craniotomy or craniectomy, the functional outcomes were similar between groups at both 6 and 12 months [
         <a href="#rid8">
          8
         </a>
         ]. However, reoperation within two weeks was more frequent in those assigned to craniotomy (15 versus 7 percent) and wound complications were more common among patients assigned to craniectomy (12 versus 4 percent).
        </p>
        <p>
         Limited observational data suggest that craniotomy is associated with better outcomes than craniostomy [
         <a href="#rid1">
          1
         </a>
         ]. In a surgical series of 60 patients with SDH, 25 patients underwent craniotomies, 24 were treated with burr holes, 8 had craniotomies with dural grafting, and 3 had decompressive craniectomies [
         <a href="#rid9">
          9
         </a>
         ]. In a subgroup of severely affected patients, patients treated with craniotomy had a lower mortality and greater functional recovery rates than those treated with burr hole surgery. However, these results should be interpreted with caution due to small patient numbers, nonrandomized treatment allocation, and differences between treatment groups [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H693500976">
         <span class="h2">
          Chronic subdural hematoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urgent recommended hematoma evacuation is required for patients with large and symptomatic chronic SDH and the potential for recovery who develop signs attributable to brain herniation or elevated ICP including for such patients with evidence of moderate to severe cognitive impairment or progressive neurologic deterioration attributable to the chronic SDH. We suggest surgical evacuation of chronic SDH for patients with clot thickness &gt;10 mm or midline shift &gt;5 mm on brain scan  (
         <a class="graphic graphic_algorithm graphicRef134178" href="/z/d/graphic/134178.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         Nonoperative management is warranted for patients with small chronic SDH that are asymptomatic or causing minimal symptoms. In addition, nonoperative management may be preferred for older patients with chronic SDH not causing elevated ICP or severe symptoms as surgical outcomes may be worse in patients age 75 years or older [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Monitoring'
         </a>
         below.)
        </p>
        <p>
         There are no expert guidelines for the management of symptomatic chronic SDH. Some authors recommend surgery for patients with acute or chronic when SDH thickness is &gt;10 mm or midline shift is &gt;5 mm based on risk of subsequent deterioration and poor outcome [
         <a href="#rid10">
          10
         </a>
         ]. In addition, surgical evacuation of chronic SDH improves outcome for symptomatic patients with evidence of brain herniation or elevated ICP [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Surgical evacuation may improve symptoms when chronic SDH causes severe cognitive impairment [
         <a href="#rid11">
          11,12
         </a>
         ]. However, some authors advocate a trial of conservative management for older adult patients with chronic SDH but no evidence of increased ICP, even when the SDH is thought to be causing or contributing to cognitive impairment. In one small series, five patients older than 70 years with persistent SDH four to five weeks after minor head trauma were observed for 30 to 45 days. These patients were symptomatic with headache and decreased cognition on the Mini Mental Status Exam at the outset of the study. Serial head computed tomography (CT) scans revealed complete disappearance or marked reduction in SDH size by 30 to 45 days, and clinical recovery was complete [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         The benefits of surgical evacuation of chronic SDH need to be balanced with surgical risks and the nonoperative natural history of chronic SDH. Chronic SDH may resolve spontaneously with nonoperative management in many cases, typically over a period of several weeks. In addition, subdural fluid can reaccumulate after surgery for chronic SDH and may lead to repeat surgery, increase risk of seizures, and higher overall treatment costs [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1105.html" rel="external">
          "Subdural hematoma in adults: Etiology, clinical features, and diagnosis", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         Available surgical options for symptomatic chronic SDH include burr hole trephination, craniotomy, and decompressive craniectomy [
         <a href="#rid1">
          1
         </a>
         ]. Endovascular treatment with middle meningeal artery embolization may be used to prevent chronic SDH recurrence or as a primary treatment for symptomatic patients who are at high risk for surgical options. In most cases, burr hold trephination is pursued. When indicated, identification and ligation of the bleeding vessel must be undertaken.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Burr hole and drainage
         </strong>
         – Burr hole trephination is performed for most patients undergoing surgery for symptomatic chronic SDH to facilitate fluid drainage and reexpansion of underlying brain tissue. One or more burr holes can be placed to allow drainage of the hematoma. A flexible catheter (Jackson–Pratt drain) is usually placed in the subdural space until the drainage subsides [
         <a href="#rid15">
          15
         </a>
         ]. The use of a drain after burr hole placement was found in one trial to reduce SDH recurrence (9 versus 24 percent) and six-month mortality (9 versus 18 percent) without an excess in medical or surgical complications [
         <a href="#rid16">
          16
         </a>
         ]. The optimal time for catheter drainage is uncertain. In a trial of 420 patients with chronic SDH assigned to burr hole drainage for either 24 or 48 hours, outcomes were similar when assessing SDH recurrence (14 versus 13 percent), as well as length of hospital stay, postoperative infections, and mortality [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A subdural evacuating port system is a less invasive alternative to craniectomy and burr hole decompression that appears safe and similarly effective in small observational studies [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Middle meningeal artery embolization
         </strong>
         – Endovascular middle meningeal artery (MMA) embolization represents a minimally invasive treatment option for the management of chronic SDH [
         <a href="#rid20">
          20,21
         </a>
         ]. MMA embolization may be used as an adjunctive option along with open techniques to decrease the likelihood of hematoma reaccumulation, including for patients with a coagulopathy and those with multiple prior SDH recurrences. It may also be performed as a sole intervention in patients deemed high surgical risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A 2021 meta-analysis of 17 retrospective and 3 prospective studies including 1416 patients with chronic SDH, those who had MMA embolization with or without initial surgical evacuation had lower rates of hematoma recurrence than those who had surgical or nonoperative management without MMA (4.8 percent versus 21.5 percent; odds ratio 0.15, 95% CI 0.03-0.75) and similar complication rates [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subsequent rescue surgery due to treatment failure after MMA embolization has been reported in 1 to 9 percent of patients in various case series [
         <a href="#rid20">
          20,21,24,25
         </a>
         ]. As an example, in a multicenter series of 138 patients with chronic SDH selected for MMA embolization, more than 70 percent achieved at least 50 percent improvement on imaging and only 7 percent underwent additional subsequent treatment [
         <a href="#rid20">
          20
         </a>
         ]. Predictors of treatment failure include pretreatment anticoagulation and MMA diameter &lt;1.5 mm [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other surgical techniques
         </strong>
         – A craniotomy with resection of membranes that surround the clot is typically performed in patients with chronic SDH that rebleed after burr hole drainage to prevent reaccumulation of fluid [
         <a href="#rid26">
          26-28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3358525960">
         <span class="h2">
          Timing of surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urgent surgical hematoma evacuation (within two to four hours) is required for patients with acute or chronic SDH and signs of brain herniation or elevated ICP and for patients who develop acute neurologic deterioration. We suggest urgent surgical hematoma evacuation for patients with clot thickness &gt;10 mm or midline shift &gt;5 mm on initial brain scan.
        </p>
        <p>
         Surgery performed within two to four hours after the onset of neurologic deterioration may be associated with a lower mortality than delayed surgery [
         <a href="#rid1">
          1,29-32
         </a>
         ]. Data from observational studies have found mortality rates between 30 and 47 percent with urgent surgery compared with 80 to 90 percent when intervention was delayed beyond four hours [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         However, other observational studies evaluating the time between injury and surgery have reported no significant relationship with outcome [
         <a href="#rid33">
          33-38
         </a>
         ], and some reports found that early intervention appeared to have a worse outcome than delayed surgery [
         <a href="#rid1">
          1,9,35,39
         </a>
         ]. These data may be confounded by selection bias, since patients who had immediate surgery tended to have more severe injuries and lower initial GCS scores than those in whom intervention was delayed [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3709195401">
         <span class="h1">
          NONOPERATIVE MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H829403091">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients with SDH managed nonoperatively, we use serial neurologic examinations and repeat imaging, typically with head computed tomography (CT), to assess for subsequent deterioration and the development of increased intracranial pressure (ICP).
        </p>
        <p>
         No randomized trials have compared surgery with conservative management for patients with SDH, but limited observational data suggest that patients with acute SDH who are clinically stable and have small hematomas can be managed nonoperatively [
         <a href="#rid4">
          4,40,41
         </a>
         ]. In a series of 65 comatose patients with acute SDH, 15 patients were selected for nonoperative management because they were clinically stable or improved from the time of injury to evaluation, had hematoma thickness &lt;10 mm and midline shift &lt;5 mm on initial head CT, and had no evidence of uncompensated ICP elevation with invasive monitoring [
         <a href="#rid40">
          40
         </a>
         ]. A good functional outcome was achieved in 10 of 15 patients (67 percent) initially managed nonoperatively compared with 13 of 50 patients (26 percent) who initially required with surgery. Only two patients in the nonoperative group had delayed surgical evacuation due to the development of parenchymal hematomas or elevated ICP.
        </p>
        <p class="headingAnchor" id="H3681060798">
         <span class="h3">
          Serial clinical examinations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical setting
         </strong>
         – Patients with an acute or symptomatic chronic SDH should be monitored in an inpatient setting with neurosurgical expertise. Those at risk for respiratory failure with impairment of alertness, coma, or other severe neurologic deficits should be admitted to an intensive care unit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other patients with small, asymptomatic chronic SDH that are found incidentally on imaging may be monitored in the ambulatory setting with initial clinical exam and follow-up imaging to document resolution of the hematoma. (See
         <a class="local">
          'Follow-up imaging'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Parameters to monitor
         </strong>
         – Neurologic examinations should include assessments of alertness, pupillary and other bulbar functions, and sensorimotor functions. For patients with baseline impairment of alertness or weakness, serial testing with Glasgow Coma Scale (GCS) score  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 2
         </a>
         ) is also performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Invasive monitoring of ICP is indicated for patients with SDH due to trauma and those with other risk factors for developing elevated ICP. This is presently separately. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults", section on 'Indications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring frequency
         </strong>
         – For patients hospitalized with acute or chronic SDH, serial neurologic examinations should be performed at baseline and every one to two hours for at least the first 24 hours after presentation. The frequency of examinations may be reduced to every four hours for stable patients. A longer interval of initial monitoring or more frequent examinations may be performed for those at higher risk for hematoma expansion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk factors for hematoma expansion include [
         <a href="#rid41">
          41-43
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Older age
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of hypertension
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of ischemic heart disease
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antithrombotic medication exposure
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Impaired consciousness on examination
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         SDH associated with additional intracranial injuries
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Larger SDH volume
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presence of intraventricular hemorrhage
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The risk of hematoma enlargement and neurologic deterioration may be highest in the first 36 hours after SDH onset [
         <a href="#rid44">
          44
         </a>
         ]. However, SDH expansion or clinical deterioration may occur hours to weeks after injury in patients with SDH. In a study of 31 patients with traumatic SDH who were initially managed nonoperatively, surgery for neurologic deterioration was required in six patients within three days of injury [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2966839866">
         <span class="h3">
          Follow-up imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that surveillance follow-up head CT be obtained within six to eight hours of the initial scan for all patients hospitalized with acute and symptomatic chronic SDH who are managed nonoperatively [
         <a href="#rid40">
          40
         </a>
         ]. The incidence of hematoma expansion is highest in the initial several hours after onset [
         <a href="#rid42">
          42,44
         </a>
         ]. Hematoma expansion may precede clinical deterioration and patients selected for initial nonoperative management may develop an indication for surgery due to progressive findings on follow-up imaging. (See
         <a class="local">
          'Identifying patients with an indication for surgery'
         </a>
         above.)
        </p>
        <p>
         For patients with stable findings on initial follow-up head CT, subsequent imaging may be performed at transitions of care (eg, prior to hospital discharge) to document stability. In addition, for patients resuming antithrombotic medications that were discontinued during initial management, follow-up head CT is typically obtained prior to resuming antithrombotic medications to document resolution of the hematoma. (See
         <a class="local">
          'Resumption of antithrombotic medications'
         </a>
         below.)
        </p>
        <p>
         Follow-up imaging is also performed for patients with acute or chronic SDH to document resolution after recovery. The timing of imaging varies by size and acuity of the SDH. Resolution of acute bleeding may be found several days up to two weeks from onset, while resolution of chronic SDH may occur several weeks after onset. (See
         <a class="medical medical_review" href="/z/d/html/1105.html" rel="external">
          "Subdural hematoma in adults: Etiology, clinical features, and diagnosis", section on 'Imaging features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1105.html" rel="external">
          "Subdural hematoma in adults: Etiology, clinical features, and diagnosis", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         Urgent repeat head CT is warranted for all patients with clinical deterioration. (See
         <a class="local">
          'Management of patients who deteriorate'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2727862844">
         <span class="h2">
          Management of patients who deteriorate
         </span>
        </p>
        <p class="headingAnchor" id="H4275723860">
         <span class="h3">
          Urgent repeat imaging to assess for indication for surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urgent repeat imaging with head CT is warranted to assess for progression of the hematoma, brain compression, or hydrocephalus in all patients with SDH who have an acute deterioration in clinical status.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with progression of hematoma
         </strong>
         – We recommend surgical evacuation when repeat head CT shows progression that meets imaging criteria for surgery. (See
         <a class="local">
          'Surgical indications and approaches'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with clinical deterioration and modest SDH progression on repeat head CT (eg, SDH that is larger than prior study but &lt;10 mm thickness) that does not meet imaging criteria for surgical evacuation, we use clinical status to guide subsequent therapy. (See
         <a class="local">
          'Surgical indications and approaches'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We recommend surgical evacuation for patients with rapid or significant clinical deterioration that is attributable to hematoma expansion (eg, pupillary changes, progressive hemiparesis contralateral to SDH). We also recommend surgical evacuation for patients with evidence of elevated ICP such as new drowsiness, development of the Cushing triad, or a drop of ≥2 points on GCS score  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Surgical indications and approaches'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For those with minor clinical changes and modest progression on repeat head CT, we may continue close nonoperative monitoring. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with clinical deterioration that is not attributable to hematoma expansion or elevated ICP, we pursue additional testing to identify the source. As an example, a patient with new isolated aphasia in the setting of a right hemisphere SDH that progressed from 4 mm to 6 mm maximal thickness may require additional testing for seizure or ischemic stroke. (See
         <a class="local">
          'Testing for other causes of deterioration when repeat imaging is stable'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with elevated intracranial pressure
         </strong>
         – Patients with SDH may develop elevated ICP requiring urgent intervention. For patients managed nonoperatively with an ICP monitor, we recommend urgent surgical evacuation if the ICP is persistently &gt;20 mmHg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Definitive therapy for elevated ICP is usually hematoma evacuation; medical resuscitation used as a temporizing measure for patients awaiting surgery includes head elevation, hyperventilation, and osmotic diuresis with intravenous
         <a class="drug drug_general" data-topicid="9587" href="/z/d/drug information/9587.html" rel="external">
          mannitol
         </a>
         or hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . The management of elevated ICP is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">
          "Evaluation and management of elevated intracranial pressure in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H170842929">
         <span class="h3">
          Testing for other causes of deterioration when repeat imaging is stable
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with SDH are at risk of clinical deterioration due to neurologic events other than hematoma expansion or elevated ICP. Additional testing is warranted for patients with SDH and evidence of clinical deterioration not accounted for by findings on repeat head CT. Specific testing is determined by clinical features and patient risk factors.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizures
         </strong>
         – SDH may cause seizures due to compression of underlying cerebral cortex. Seizures may accompany acute SDH in the setting of mild or severe traumatic brain injury. (See
         <a class="medical medical_review" href="/z/d/html/2213.html" rel="external">
          "Posttraumatic seizures and epilepsy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with a persistent impairment in alertness not due to elevated ICP, those with fluctuating changes in neurologic examination, and those with witnessed convulsions warrant evaluation for seizures with electroencephalography.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ischemic stroke
         </strong>
         – SDH may be complicated by ischemic stroke in patients with thromboembolic risk factors such as atrial fibrillation due to the reversal of anticoagulation to manage the SDH. In addition, ischemic stroke may infrequently occur in nonambulatory patients in the setting of embolization of a deep venous thrombosis. (See
         <a class="medical medical_review" href="/z/d/html/1092.html" rel="external">
          "Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults", section on 'Paradoxical emboli'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ischemic stroke should be suspected in at-risk patients with SDH who have a sudden clinical deterioration consistent with ischemic stroke  (
         <a class="graphic graphic_table graphicRef71676" href="/z/d/graphic/71676.html" rel="external">
          table 5
         </a>
         ) and stable head CT. Brain magnetic resonance imaging (MRI) is the preferred imaging modality because acute ischemic stroke may not be visible on initial repeat head CT. The treatment of acute ischemic stroke is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">
          "Initial assessment and management of acute stroke"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute toxic-metabolic encephalopathy
         </strong>
         – Patients with SDH may develop delirium due several causes including preexisting medical conditions, pain, or medications. The evaluation of patients with delirium is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">
          "Diagnosis of delirium and confusional states"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H895710504">
         <span class="h2">
          Evaluation for underlying causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with spontaneous SDH not associated with trauma or other obvious cause may warrant brain and/or vascular imaging and other testing to identify possible secondary causes. The evaluation of underlying causes of SDH is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1105.html" rel="external">
          "Subdural hematoma in adults: Etiology, clinical features, and diagnosis", section on 'Evaluation for underlying causes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4169346203">
         <span class="h2">
          Prevention and management of medical complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute or chronic SDH are at risk for medical complications due to immobility or direct effects of the SDH. These complications can be associated with worse outcomes based on data from patients with intracerebral hemorrhage [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Seizure prophylaxis and management
         </strong>
         – Patients with SDH are at risk for seizure or status epilepticus [
         <a href="#rid46">
          46
         </a>
         ]. We do
         <strong>
          not
         </strong>
         routinely start antiseizure medicine prophylaxis for patients who have not had a seizure. In systematic reviews and observational studies, the seizure rate appears similar whether or not patients with SDH receive antiseizure medication prophylaxis [
         <a href="#rid46">
          46-49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with impairment of consciousness not attributed to mass effect from the SDH, we evaluate for other causes of symptoms. This includes electroencephalography to assess for nonconvulsive seizures or status epilepticus. (See
         <a class="local">
          'Evaluation for underlying causes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Antiseizure medications are typically reserved for patients with SDH who have clinical or electrographic seizures. The choice of initial antiseizure medication is guided by medical comorbidities, drug interactions, side effect drug profile, and contraindications  (
         <a class="graphic graphic_table graphicRef60182" href="/z/d/graphic/60182.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">
          "Evaluation and management of the first seizure in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of venous thromboembolism
         </strong>
         – Patients hospitalized with an acute illness and those with a neurologic condition that impairs mobility are at risk for venous thromboembolism. Intermittent pneumatic compression should be started on the first day of hospital admission for patients with SDH and impaired mobility. We add chemical prophylaxis for most patients one to four days after SDH stability is documented. An exception would be some patients being evaluated for urgent surgery for whom chemical prophylaxis may be temporarily withheld. (See
         <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">
          "Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2342495289">
         <span class="h2">
          Therapies not recommended or of uncertain benefit
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Statin medications
         </strong>
         – Limited data suggest that low-dose statin medications may reduce hematoma size for patients with chronic SDH. In a systematic review that identified 156 patients with chronic SDH from three observational studies,
         <a class="drug drug_general" data-topicid="8949" href="/z/d/drug information/8949.html" rel="external">
          atorvastatin
         </a>
         20 mg daily for one to six months was associated with reduced hematoma volume and low rates of recurrence [
         <a href="#rid50">
          50
         </a>
         ]. In a trial of 196 patients with chronic SDH from China, those assigned atorvastatin 20 mg daily had better outcomes at eight weeks than those assigned to placebo, including greater reduction in SDH volumes (29 versus 17 mL) and lower rates of surgery for hematoma enlargement or deterioration (11 versus 24 percent; hazard ratio 0.47, 95% CI 0.24-0.92) [
         <a href="#rid51">
          51
         </a>
         ]. Additional studies are needed to better identify the role of statin medications in the nonoperative management of patients with chronic SDH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10011" href="/z/d/drug information/10011.html" rel="external">
          Tranexamic acid
         </a>
         – The role of tranexamic acid (TXA) in the nonoperative management of patients with SDH is uncertain. TXA is an antifibrinolytic agent used in some patients with chronic SDH to reduce the rate of rebleeding after surgery or to promote resorption [
         <a href="#rid52">
          52
         </a>
         ]. In a systematic review of 105 patients from four studies, only low-quality evidence was identified showing that tranexamic acid was associated with reduction in hematoma volume [
         <a href="#rid53">
          53
         </a>
         ]. Data were limited by small numbers and variability in patient characteristics. In addition, TXA was used as an adjunctive therapy to surgical evacuation in most cases. In an observational study of 27 patients with chronic SDH managed nonoperatively including TXA for a mean of 65 days, resolution occurred in all patients and no complications were reported [
         <a href="#rid54">
          54
         </a>
         ]. Additional trial data are needed to clarify the role of TXA for patients with chronic SDH.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glucocorticoids
         </strong>
         – We
         <strong>
          avoid
         </strong>
         glucocorticoid therapy for patients with SDH. In a trial of 748 patients with symptomatic chronic SDH, those assigned to a two-week course of
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         were less likely to achieve a good functional outcome at six months than those assigned to placebo (84 versus 90 percent) [
         <a href="#rid55">
          55
         </a>
         ]. Glucocorticoid therapy has also been associated with increased acute mortality following head injury. This issue is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4826.html" rel="external">
          "Management of acute moderate and severe traumatic brain injury", section on 'Glucocorticoids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H856467787">
         <span class="h1">
          PROGNOSIS AND LONG-TERM MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of SDH depends on severity of SDH and associated medical comorbidities. In a study that included 746 procedures of patients with SDH who underwent surgery between 2005 and 2012, the 30-day mortality rate was 17 percent [
         <a href="#rid56">
          56
         </a>
         ]. In another study assessing outcome of patients undergoing surgery for acute SDH that included 462 patients (median age 49 years old), mortality at six months was 31 percent [
         <a href="#rid8">
          8
         </a>
         ]. The estimated mortality rate for patients with more severe injuries who require surgery for SDH is as high as 60 percent in some small studies [
         <a href="#rid1">
          1,3,9,29,33,40
         </a>
         ]. For patients who presented with coma prior to surgical evacuation, mortality rates were 57 to 68 percent [
         <a href="#rid1">
          1,34,57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1420059689">
         <span class="h2">
          Risk factors for poor outcome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Age greater than 60 years and severe neurologic impairment are important prognostic indicators in patients with acute SDH [
         <a href="#rid9">
          9,34
         </a>
         ]. Clinical features associated with poor outcome after SDH include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older age [
         <a href="#rid34">
          34,56
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lower Glasgow Coma Scale score [
         <a href="#rid9">
          9,39
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coma at presentation [
         <a href="#rid56">
          56,57
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coagulopathy [
         <a href="#rid1">
          1,56,58
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         In addition, several studies have identified head computed tomography (CT) findings that correlate with poor outcome after acute SDH, including the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematoma thickness [
         <a href="#rid3">
          3,35
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematoma volume [
         <a href="#rid36">
          36
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence and/or degree of midline brain shift [
         <a href="#rid3">
          3,34-36
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced patency of the basal cisterns [
         <a href="#rid35">
          35
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coexisting intraparenchymal injury [
         <a href="#rid33">
          33,58
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arterial source to SDH [
         <a href="#rid59">
          59,60
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         However, some studies have not confirmed these relationships [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1054284492">
         <span class="h2">
          Risk of recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrence of an acute SDH after initial resolution is uncommon and usually associated with an underlying fixed bleeding source such as a dural arteriovenous malformation, metastases, liver failure, hematological malignancies, or intracranial hypotension [
         <a href="#rid62">
          62-65
         </a>
         ]. The risk of recurrence may be higher in patients with spontaneous SDH than those with a clear precipitant such as trauma.
        </p>
        <p>
         Recurrence of chronic SDH has been described in 5 up to 30 percent of patients [
         <a href="#rid66">
          66-68
         </a>
         ]. Older age, thicker hematoma width, and bilateral presentation have been linked to higher rates of recurrence [
         <a href="#rid68">
          68-73
         </a>
         ]. Ongoing antiplatelet and anticoagulant therapy may also increase the risk of recurrent SDH, although this has not been consistently found [
         <a href="#rid72">
          72,74,75
         </a>
         ]. The use of postoperative drainage is associated with a lower risk of secondary recurrence.
        </p>
        <p class="headingAnchor" id="H3550165179">
         <span class="h2">
          Resumption of antithrombotic medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to resume anticoagulant or antiplatelet medications that were discontinued during initial SDH management should be individualized balancing the strength of the specific indication for therapy with the risk of SDH recurrence.
        </p>
        <p>
         We suggest resuming antiplatelet therapy after SDH resolution for most patients with a specific indication for such therapy. In one study of 2939 patients with SDH, the risk of subsequent arterial ischemic events was elevated in the first four weeks after SDH (hazard ratio 3.6, 95% CI 1.9-5.5), driven largely by patients with strong indications for antithrombotic therapy [
         <a href="#rid76">
          76
         </a>
         ]. Accordingly, the risk-benefit analysis might favor resumption of antiplatelet therapy in a patient with active coronary or vascular disease, particularly after a SDH related to a traumatic injury that was not likely to recur.
        </p>
        <p>
         Many patients will benefit from resuming anticoagulation when the thromboembolic risk is higher than the risk of recurrent SDH. The specific risks and benefits should be weighed for individual patients. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticoagulation may be resumed for selected patients with a traumatic SDH and atrial fibrillation with an elevated risk of thromboembolism after follow-up head CT shows resolution of the hematoma. (See
         <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">
          "Atrial fibrillation in adults: Selection of candidates for anticoagulation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticoagulation may be resumed for selected patients with a spontaneous SDH and a history of deep venous thrombosis and a high recurrence risk after follow-up head CT shows resolution of the hematoma. (See
         <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">
          "Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation", section on 'High recurrence risk'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticoagulation may be
         <strong>
          withheld
         </strong>
         for selected patients with SDH and a high risk of recurrence, such as those with SDH due to a secondary source such as an unsecured arteriovenous malformation that has bled or cerebral amyloid angiopathy. (See
         <a class="medical medical_review" href="/z/d/html/1087.html" rel="external">
          "Brain arteriovenous malformations", section on 'Ruptured AVMs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1128.html" rel="external">
          "Cerebral amyloid angiopathy", section on 'Managing anticoagulant and antiplatelet medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Limited data suggest anticoagulation can be safely resumed following SDH in properly selected patients. In a meta-analysis of observational studies of the postoperative course of patients with chronic SDH, hemorrhagic complications were similar among those who resumed or discontinued anticoagulation [
         <a href="#rid77">
          77
         </a>
         ]. However, the subsequent thromboembolic rate was lower among patients who resumed anticoagulation (3 versus 7 percent). In an analysis of 98 patients with chronic SDH who underwent surgical evacuation, the subsequent SDH recurrence rate was similar among those who started long-term anticoagulation and propensity score-matched patients who did not [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1812979090">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/105370.html" rel="external">
          "Society guideline links: Stroke in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H131028869">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17230.html" rel="external">
          "Patient education: Subdural hematoma and epidural hematoma (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial management
         </strong>
         – Subdural hematoma (SDH) can be a neurologic emergency that may cause irreversible brain injury and death caused by hematoma expansion, elevated intracranial pressure (ICP), and brain herniation. Patients with SDH require urgent assessment of clinical status, the management of any antithrombotic medications, and evaluation of the need for immediate surgery  (
         <a class="graphic graphic_table graphicRef132691" href="/z/d/graphic/132691.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Initial management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical management
         </strong>
         – Urgent surgical hematoma evacuation is required for patients with SDH and signs attributable to brain herniation or elevated ICP and for those with clinical deterioration due to hematoma expansion  (
         <a class="graphic graphic_algorithm graphicRef134178" href="/z/d/graphic/134178.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Surgical indications and approaches'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We also suggest surgical hematoma evacuation for patients with clot thickness &gt;10 mm or midline shift &gt;5 mm on initial brain scan especially if there is neurologic deterioration (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For other patients, we monitor nonoperatively with close neurologic monitoring for clinical or radiographic deterioration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonoperative management for all others
         </strong>
         – Nonoperative management of SDH may be appropriate for patients who are clinically stable and have small hematomas with no signs of brain herniation (ie, midline shift &lt;5 mm) or elevated ICP. Patients with SDH managed nonoperatively are closely monitored to assess for subsequent deterioration  (
         <a class="graphic graphic_algorithm graphicRef134178" href="/z/d/graphic/134178.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Nonoperative management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring
         </strong>
         – Neurologic examinations should be performed at baseline and every one to two hours for at least the first 24 hours. Examinations include assessments of alertness, pupillary and other bulbar functions, sensorimotor functions, and Glasgow Coma Scale scoring  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Repeat imaging
         </strong>
         – Surveillance follow-up imaging with head computed tomography (CT) should be obtained within six to eight hours of the initial scan for all patients with SDH. Urgent repeat head CT is warranted for all patients who have an acute deterioration in clinical status. (See
         <a class="local">
          'Follow-up imaging'
         </a>
         above and
         <a class="local">
          'Urgent repeat imaging to assess for indication for surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients who deteriorate
         </strong>
         – Surgical evacuation is indicated when clinical deterioration is due to significant progression of the hematoma. Testing for other causes is warranted for patients with SDH and evidence of clinical deterioration not accounted for by findings on repeat head CT. (See
         <a class="local">
          'Management of patients who deteriorate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Resumption of antithrombotic medications
         </strong>
         – The decision should be individualized balancing the strength of the specific indication for therapy with the risk of SDH recurrence. Many patients will benefit from resuming anticoagulation when the thromboembolic risk is higher than the risk of recurrent SDH. (See
         <a class="local">
          'Resumption of antithrombotic medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The 30-day mortality rate in patients with SDH who underwent surgery is approximately 17 percent but may be higher in patients who present with clinical features such as older age, preexisting coagulopathy, severe deficits on exam, and imaging features such as larger SDH volume, brain compression, or coexisting intraparenchymal injury. (See
         <a class="local">
          'Risk factors for poor outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. Neurosurgery 2006; 58:S16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uno M, Toi H, Hirai S. Chronic Subdural Hematoma in Elderly Patients: Is This Disease Benign? Neurol Med Chir (Tokyo) 2017; 57:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zumkeller M, Behrmann R, Heissler HE, Dietz H. Computed tomographic criteria and survival rate for patients with acute subdural hematoma. Neurosurgery 1996; 39:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong CW. Criteria for conservative treatment of supratentorial acute subdural haematomas. Acta Neurochir (Wien) 1995; 135:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phan K, Moore JM, Griessenauer C, et al. Craniotomy Versus Decompressive Craniectomy for Acute Subdural Hematoma: Systematic Review and Meta-Analysis. World Neurosurg 2017; 101:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yagnik KJ, Goyal A, Van Gompel JJ. Twist drill craniostomy vs burr hole drainage of chronic subdural hematoma: a systematic review and meta-analysis. Acta Neurochir (Wien) 2021; 163:3229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi YH, Han SR, Lee CH, et al. Delayed Burr Hole Surgery in Patients with Acute Subdural Hematoma: Clinical Analysis. J Korean Neurosurg Soc 2017; 60:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson PJ, Adams H, Mohan M, et al. Decompressive Craniectomy versus Craniotomy for Acute Subdural Hematoma. N Engl J Med 2023; 388:2219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatashita S, Koga N, Hosaka Y, Takagi S. Acute subdural hematoma: severity of injury, surgical intervention, and mortality. Neurol Med Chir (Tokyo) 1993; 33:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehta V, Harward SC, Sankey EW, et al. Evidence based diagnosis and management of chronic subdural hematoma: A review of the literature. J Clin Neurosci 2018; 50:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill M, Maheshwari V, Narang A, Lingaraju TS. Impact on Cognitive Improvement Following Burr Hole Evacuation of Chronic Subdural Hematoma: A Prospective Observational Study. J Neurosci Rural Pract 2018; 9:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaauw J, Boxum AG, Jacobs B, et al. Prevalence of Cognitive Complaints and Impairment in Patients with Chronic Subdural Hematoma and Recovery after Treatment: A Systematic Review. J Neurotrauma 2021; 38:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parlato C, Guarracino A, Moraci A. Spontaneous resolution of chronic subdural hematoma. Surg Neurol 2000; 53:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rauhala M, Helén P, Huhtala H, et al. Chronic subdural hematoma-incidence, complications, and financial impact. Acta Neurochir (Wien) 2020; 162:2033.
          </a>
         </li>
         <li class="breakAll">
          Mayer S, Rowland L. Head injury. In: Merritt's Neurology, Rowland L (Ed), Lippincott Williams &amp; Wilkins, 2000. p.401.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santarius T, Kirkpatrick PJ, Ganesan D, et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. Lancet 2009; 374:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen TSR, Haldrup M, Hjortdal Grønhøj M, et al. National randomized clinical trial on subdural drainage time after chronic subdural hematoma evacuation. J Neurosurg 2021; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singla A, Jacobsen WP, Yusupov IR, Carter DA. Subdural evacuating port system (SEPS)--minimally invasive approach to the management of chronic/subacute subdural hematomas. Clin Neurol Neurosurg 2013; 115:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safain M, Roguski M, Antoniou A, et al. A single center's experience with the bedside subdural evacuating port system: a useful alternative to traditional methods for chronic subdural hematoma evacuation. J Neurosurg 2013; 118:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kan P, Maragkos GA, Srivatsan A, et al. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Multi-Center Experience of 154 Consecutive Embolizations. Neurosurgery 2021; 88:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Link TW, Boddu S, Paine SM, et al. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Series of 60 Cases. Neurosurgery 2019; 85:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ironside N, Nguyen C, Do Q, et al. Middle meningeal artery embolization for chronic subdural hematoma: a systematic review and meta-analysis. J Neurointerv Surg 2021; 13:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivatsan A, Mohanty A, Nascimento FA, et al. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Meta-Analysis and Systematic Review. World Neurosurg 2019; 122:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ban SP, Hwang G, Byoun HS, et al. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma. Radiology 2018; 286:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salem MM, Kuybu O, Nguyen Hoang A, et al. Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Predictors of Clinical and Radiographic Failure from 636 Embolizations. Radiology 2023; 307:e222045.
          </a>
         </li>
         <li class="breakAll">
          Victor M, Ropper A. Craniocerebral trauma. In: Adams and Victor's Principles of Neurology, 7th ed, Victor M, Ropper A (Eds), McGraw-Hill, 2001. p.925.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JY, Ebel H, Ernestus RI, Klug N. Various surgical treatments of chronic subdural hematoma and outcome in 172 patients: is membranectomy necessary? Surg Neurol 2004; 61:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moon HG, Shin HS, Kim TH, et al. Ossified chronic subdural hematoma. Yonsei Med J 2003; 44:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haselsberger K, Pucher R, Auer LM. Prognosis after acute subdural or epidural haemorrhage. Acta Neurochir (Wien) 1988; 90:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seelig JM, Becker DP, Miller JD, et al. Traumatic acute subdural hematoma: major mortality reduction in comatose patients treated within four hours. N Engl J Med 1981; 304:1511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilberger JE Jr, Harris M, Diamond DL. Acute subdural hematoma: morbidity, mortality, and operative timing. J Neurosurg 1991; 74:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakas DE, Bullock MR, Teasdale GM. One-year outcome following craniotomy for traumatic hematoma in patients with fixed dilated pupils. J Neurosurg 1995; 82:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koç RK, Akdemir H, Oktem IS, et al. Acute subdural hematoma: outcome and outcome prediction. Neurosurg Rev 1997; 20:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotwica Z, Brzeziński J. Acute subdural haematoma in adults: an analysis of outcome in comatose patients. Acta Neurochir (Wien) 1993; 121:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Servadei F, Nasi MT, Giuliani G, et al. CT prognostic factors in acute subdural haematomas: the value of the 'worst' CT scan. Br J Neurosurg 2000; 14:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard MA 3rd, Gross AS, Dacey RG Jr, Winn HR. Acute subdural hematomas: an age-dependent clinical entity. J Neurosurg 1989; 71:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massaro F, Lanotte M, Faccani G, Triolo C. One hundred and twenty-seven cases of acute subdural haematoma operated on. Correlation between CT scan findings and outcome. Acta Neurochir (Wien) 1996; 138:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uzan M, Yentür E, Hanci M, et al. Is it possible to recover from uncal herniation? Analysis of 71 head injured cases. J Neurosurg Sci 1998; 42:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dent DL, Croce MA, Menke PG, et al. Prognostic factors after acute subdural hematoma. J Trauma 1995; 39:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Servadei F, Nasi MT, Cremonini AM, et al. Importance of a reliable admission Glasgow Coma Scale score for determining the need for evacuation of posttraumatic subdural hematomas: a prospective study of 65 patients. J Trauma 1998; 44:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew P, Oluoch-Olunya DL, Condon BR, Bullock R. Acute subdural haematoma in the conscious patient: outcome with initial non-operative management. Acta Neurochir (Wien) 1993; 121:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Givner A, Gurney J, O'Connor D, et al. Reimaging in pediatric neurotrauma: factors associated with progression of intracranial injury. J Pediatr Surg 2002; 37:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaonkar VB, Garg K, Agrawal D, et al. Risk Factors for Progression of Conservatively Managed Acute Traumatic Subdural Hematoma: A Systematic Review and Meta-Analysis. World Neurosurg 2021; 146:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oertel M, Kelly DF, McArthur D, et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg 2002; 96:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Wang Y, Ji R, et al. In-hospital complications affect short-term and long-term mortality in ICH: a prospective cohort study. Stroke Vasc Neurol 2021; 6:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pruitt P, Naidech A, Van Ornam J, Borczuk P. Seizure frequency in patients with isolated subdural hematoma and preserved consciousness. Brain Inj 2019; 33:1059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nachiappan DS, Garg K. Role of prophylactic antiepileptic drugs in chronic subdural hematoma-a systematic review and meta-analysis. Neurosurg Rev 2021; 44:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lavergne P, Labidi M, Brunet MC, et al. Efficacy of antiseizure prophylaxis in chronic subdural hematoma: a cohort study on routinely collected health data. J Neurosurg 2019; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khor D, Wu J, Hong Q, et al. Early Seizure Prophylaxis in Traumatic Brain Injuries Revisited: A Prospective Observational Study. World J Surg 2018; 42:1727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qiu S, Zhuo W, Sun C, et al. Effects of atorvastatin on chronic subdural hematoma: A systematic review. Medicine (Baltimore) 2017; 96:e7290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang R, Zhao S, Wang R, et al. Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial. JAMA Neurol 2018; 75:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada T, Natori Y. Prospective Study on the Efficacy of Orally Administered Tranexamic Acid and Goreisan for the Prevention of Recurrence After Chronic Subdural Hematoma Burr Hole Surgery. World Neurosurg 2020; 134:e549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scerrati A, Visani J, Ricciardi L, et al. To drill or not to drill, that is the question: nonsurgical treatment of chronic subdural hematoma in the elderly. A systematic review. Neurosurg Focus 2020; 49:E7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutty RK, Leela SK, Sreemathyamma SB, et al. The Outcome of Medical Management of Chronic Subdural Hematoma with Tranexamic Acid - A Prospective Observational Study. J Stroke Cerebrovasc Dis 2020; 29:105273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchinson PJ, Edlmann E, Bulters D, et al. Trial of Dexamethasone for Chronic Subdural Hematoma. N Engl J Med 2020; 383:2616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lukasiewicz AM, Grant RA, Basques BA, et al. Patient factors associated with 30-day morbidity, mortality, and length of stay after surgery for subdural hematoma: a study of the American College of Surgeons National Surgical Quality Improvement Program. J Neurosurg 2016; 124:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gennarelli TA, Spielman GM, Langfitt TW, et al. Influence of the type of intracranial lesion on outcome from severe head injury. J Neurosurg 1982; 56:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hlatky R, Valadka AB, Goodman JC, Robertson CS. Evolution of brain tissue injury after evacuation of acute traumatic subdural hematomas. Neurosurgery 2004; 55:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur G, Dakay K, Sursal T, et al. Acute subdural hematomas secondary to aneurysmal subarachnoid hemorrhage confer poor prognosis: a national perspective. J Neurointerv Surg 2021; 13:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulcahy MJ, Chaganti J, Dower A, Al-Khawaja D. Spontaneous Acute Arterial Subdural Hematoma. World Neurosurg 2018; 110:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Brink WA, Zwienenberg M, Zandee SM, et al. The prognostic importance of the volume of traumatic epidural and subdural haematomas revisited. Acta Neurochir (Wien) 1999; 141:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maiuri F, Iaconetta G, Sardo L, Briganti F. Dural arteriovenous malformation associated with recurrent subdural haematoma and intracranial hypertension. Br J Neurosurg 2001; 15:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizuno J, Mummaneni PV, Rodts GE, Barrow DL. Recurrent subdural hematoma caused by cerebrospinal fluid leakage. Case report. J Neurosurg Spine 2006; 4:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Morales I, Porta-Etessam J, Galán L, et al. Recurrent subdural haematomas in a patient with spontaneous intracranial hypotension. Cephalalgia 2001; 21:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schievink WI, Maya MM, Pikul BK, Louy C. Spontaneous spinal cerebrospinal fluid leaks as the cause of subdural hematomas in elderly patients on anticoagulation. J Neurosurg 2010; 112:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santarius T, Qureshi HU, Sivakumaran R, et al. The role of external drains and peritoneal conduits in the treatment of recurrent chronic subdural hematoma. World Neurosurg 2010; 73:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlsen JG, Cortnum S, Sørensen JC. Recurrence of chronic subdural haematomata with and without post-operative drainage. Br J Neurosurg 2011; 25:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu GJ, Han CZ, Zhang M, et al. Prolonged drainage reduces the recurrence of chronic subdural hematoma. Br J Neurosurg 2009; 23:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escosa Baé M, Wessling H, Salca HC, de Las Heras Echeverría P. Use of twist-drill craniostomy with drain in evacuation of chronic subdural hematomas: independent predictors of recurrence. Acta Neurochir (Wien) 2011; 153:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oh HJ, Lee KS, Shim JJ, et al. Postoperative course and recurrence of chronic subdural hematoma. J Korean Neurosurg Soc 2010; 48:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kung WM, Hung KS, Chiu WT, et al. Quantitative assessment of impaired postevacuation brain re-expansion in bilateral chronic subdural haematoma: possible mechanism of the higher recurrence rate. Injury 2012; 43:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torihashi K, Sadamasa N, Yoshida K, et al. Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases. Neurosurgery 2008; 63:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto H, Hirashima Y, Hamada H, et al. Independent predictors of recurrence of chronic subdural hematoma: results of multivariate analysis performed using a logistic regression model. J Neurosurg 2003; 98:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forster MT, Mathé AK, Senft C, et al. The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. J Clin Neurosci 2010; 17:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindvall P, Koskinen LO. Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas. J Clin Neurosci 2009; 16:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murthy SB, Wu X, Diaz I, et al. Non-Traumatic Subdural Hemorrhage and Risk of Arterial Ischemic Events. Stroke 2020; 51:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phan K, Abi-Hanna D, Kerferd J, et al. Resumption of Antithrombotic Agents in Chronic Subdural Hematoma: A Systematic Review and Meta-analysis. World Neurosurg 2018; 109:e792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salih M, Young M, Shutran M, et al. Effect of long-term anticoagulant therapy on the outcome of chronic subdural hematoma: a propensity score-matched analysis. J Neurosurg 2023; 139:194.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1110 Version 27.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16710968" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Surgical management of acute subdural hematomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28652561" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Chronic Subdural Hematoma in Elderly Patients: Is This Disease Benign?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8880762" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Computed tomographic criteria and survival rate for patients with acute subdural hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8748790" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Criteria for conservative treatment of supratentorial acute subdural haematomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28315797" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Craniotomy Versus Decompressive Craniectomy for Acute Subdural Hematoma: Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34647183" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Twist drill craniostomy vs burr hole drainage of chronic subdural hematoma: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29142632" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Delayed Burr Hole Surgery in Patients with Acute Subdural Hematoma: Clinical Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37092792" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Decompressive Craniectomy versus Craniotomy for Acute Subdural Hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7680777" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acute subdural hematoma: severity of injury, surgical intervention, and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29428263" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Evidence based diagnosis and management of chronic subdural hematoma: A review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30271033" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Impact on Cognitive Improvement Following Burr Hole Evacuation of Chronic Subdural Hematoma: A Prospective Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32873143" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Prevalence of Cognitive Complaints and Impairment in Patients with Chronic Subdural Hematoma and Recovery after Treatment: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10825513" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Spontaneous resolution of chronic subdural hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32524244" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Chronic subdural hematoma-incidence, complications, and financial impact.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32524244" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Chronic subdural hematoma-incidence, complications, and financial impact.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19782872" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34972091" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : National randomized clinical trial on subdural drainage time after chronic subdural hematoma evacuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22763191" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Subdural evacuating port system (SEPS)--minimally invasive approach to the management of chronic/subacute subdural hematomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23259822" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A single center's experience with the bedside subdural evacuating port system: a useful alternative to traditional methods for chronic subdural hematoma evacuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33026434" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Multi-Center Experience of 154 Consecutive Embolizations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30418606" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: A Series of 60 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34193592" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Middle meningeal artery embolization for chronic subdural hematoma: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30481628" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Meta-Analysis and Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29019449" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Middle Meningeal Artery Embolization for Chronic Subdural Hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37070990" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Predictors of Clinical and Radiographic Failure from 636 Embolizations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37070990" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: Predictors of Clinical and Radiographic Failure from 636 Embolizations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15165784" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Various surgical treatments of chronic subdural hematoma and outcome in 172 patients: is membranectomy necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14584111" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Ossified chronic subdural hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3354356" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prognosis after acute subdural or epidural haemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7231489" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Traumatic acute subdural hematoma: major mortality reduction in comatose patients treated within four hours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1988590" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acute subdural hematoma: morbidity, mortality, and operative timing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7760198" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : One-year outcome following craniotomy for traumatic hematoma in patients with fixed dilated pupils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9457718" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Acute subdural hematoma: outcome and outcome prediction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8512021" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Acute subdural haematoma in adults: an analysis of outcome in comatose patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10889882" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : CT prognostic factors in acute subdural haematomas: the value of the 'worst' CT scan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2585078" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Acute subdural hematomas: an age-dependent clinical entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8686543" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : One hundred and twenty-seven cases of acute subdural haematoma operated on. Correlation between CT scan findings and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9826793" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Is it possible to recover from uncal herniation? Analysis of 71 head injured cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7636908" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Prognostic factors after acute subdural hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9603091" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Importance of a reliable admission Glasgow Coma Scale score for determining the need for evacuation of posttraumatic subdural hematomas: a prospective study of 65 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8512003" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Acute subdural haematoma in the conscious patient: outcome with initial non-operative management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11877652" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Reimaging in pediatric neurotrauma: factors associated with progression of intracranial injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33197632" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Risk Factors for Progression of Conservatively Managed Acute Traumatic Subdural Hematoma: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11794591" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33122255" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : In-hospital complications affect short-term and long-term mortality in ICH: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31007086" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Seizure frequency in patients with isolated subdural hematoma and preserved consciousness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32910368" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Role of prophylactic antiepileptic drugs in chronic subdural hematoma-a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30660118" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Efficacy of antiseizure prophylaxis in chronic subdural hematoma: a cohort study on routinely collected health data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29159600" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Early Seizure Prophylaxis in Traumatic Brain Injuries Revisited: A Prospective Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28658127" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effects of atorvastatin on chronic subdural hematoma: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30073290" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31678452" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prospective Study on the Efficacy of Orally Administered Tranexamic Acid and Goreisan for the Prevention of Recurrence After Chronic Subdural Hematoma Burr Hole Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33002869" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : To drill or not to drill, that is the question: nonsurgical treatment of chronic subdural hematoma in the elderly. A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33066896" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The Outcome of Medical Management of Chronic Subdural Hematoma with Tranexamic Acid - A Prospective Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33326713" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Trial of Dexamethasone for Chronic Subdural Hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26315000" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Patient factors associated with 30-day morbidity, mortality, and length of stay after surgery for subdural hematoma: a study of the American College of Surgeons National Surgical Quality Improvement Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7054419" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Influence of the type of intracranial lesion on outcome from severe head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15574213" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Evolution of brain tissue injury after evacuation of acute traumatic subdural hematomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32769111" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Acute subdural hematomas secondary to aneurysmal subarachnoid hemorrhage confer poor prognosis: a national perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29203309" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Spontaneous Acute Arterial Subdural Hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10392207" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The prognostic importance of the volume of traumatic epidural and subdural haematomas revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11478069" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Dural arteriovenous malformation associated with recurrent subdural haematoma and intracranial hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16506488" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Recurrent subdural hematoma caused by cerebrospinal fluid leakage. Case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11531906" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Recurrent subdural haematomas in a patient with spontaneous intracranial hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19199465" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Spontaneous spinal cerebrospinal fluid leaks as the cause of subdural hematomas in elderly patients on anticoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20934168" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The role of external drains and peritoneal conduits in the treatment of recurrent chronic subdural hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21501053" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Recurrence of chronic subdural haematomata with and without post-operative drainage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19922274" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Prolonged drainage reduces the recurrence of chronic subdural hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21193935" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Use of twist-drill craniostomy with drain in evacuation of chronic subdural hematomas: independent predictors of recurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21430978" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Postoperative course and recurrence of chronic subdural hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20850740" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Quantitative assessment of impaired postevacuation brain re-expansion in bilateral chronic subdural haematoma: possible mechanism of the higher recurrence rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19008766" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12816267" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Independent predictors of recurrence of chronic subdural hematoma: results of multivariate analysis performed using a logistic regression model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20580997" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19564115" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Anticoagulants and antiplatelet agents and the risk of development and recurrence of chronic subdural haematomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32178587" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Non-Traumatic Subdural Hemorrhage and Risk of Arterial Ischemic Events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29107160" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Resumption of Antithrombotic Agents in Chronic Subdural Hematoma: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36681947" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effect of long-term anticoagulant therapy on the outcome of chronic subdural hematoma: a propensity score-matched analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
